12 results about "Stem cell marker" patented technology

The present invention relates to a composition for the prevention or treatment of cisplatin-resistant cancer comprising an inhibitor of DUSP23 expression or activity as an active ingredient. It was found that DUSP23 expression is upregulated in cell clusters exhibiting characteristics of cancer stem cells, and that knocking down DUSP23 significantly reduces cell cluster formation as well as decreases the expression of SOX2, a major stem cell marker. Furthermore, DUSP23 expression was increased in lung cancer cells that had developed cisplatin resistance, and it was confirmed that the downregulation of DUSP23 inhibits self-renewal and invasive capabilities during the induction of cancer cell death. In addition, it was confirmed that DUSP23 plays an important role in promoting cancer stem cell characteristics through SOX2 expression. In conclusion, it has been shown that targeting DUSP23 can be a promising therapeutic strategy to overcome anticancer drug resistance in lung cancer, and the composition of the present invention is expected to be usefully utilized as a treatment for lung cancer cells with cisplatin resistance.

The application relates to the technical field of nanomaterials, and particularly discloses a kind of nanomaterials for stem cell labeling and photoacoustic imaging, a preparation method and application thereof.The application provides a new method capable of stably labeling high-performance photoacoustic nanomaterials on the surface of stem cells in a quick, efficient, specific and non-damaging manner to cell functions, so as to realize high signal-to-noise ratio and long-term dynamic in-vivo tracing of stem cell transplantation fate, and overcome multiple limitations of traditional endocytosis labeling in efficiency, timeliness, specificity and cell compatibility.

The invention discloses an application of SETD2 and NSD2 in diagnosis and treatment of aging of intestinal stem cells. Specifically, the invention relates to application of the intestinal stem cell aging marker or the detection reagent thereof, the intestinal stem cell aging marker or the detection reagent thereof is used for preparing a diagnostic reagent or a diagnostic kit, and the diagnostic reagent or the diagnostic kit is used for judging whether intestinal stem cells are aged or not. Wherein the senescence marker combination is prepared from SETD2 and NSD2 (National Solution Development 2). Meanwhile, the invention provides a detection reagent and a kit for the intestinal stem cell marker. The detection reagent or the kit can effectively judge the aging type of the intestinal stem cells, and different effective drugs are effectively used according to different types.

The invention provides application of Mafb as a target spot in promotion of diabetic corneal epithelium injury repair, and belongs to the technical field of biological medicine. According to the application, the Mafb gene is taken as a treatment target, the repair speed of corneal epithelium injury can be obviously accelerated by over-expressing the Mafb gene in the cornea of a diabetic patient, and the expression levels of stem cell markers and cell proliferation markers in corneal epithelium tissues are obviously up-regulated. The invention also provides a recombinant adeno-associated virus AAV9-Mafb for overexpressing the Mafb gene, and the AAV9-Mafb can significantly recover the function of the corneal limbal stem cells of the diabetic mouse and promote the proliferation of corneal epithelial cells, thereby accelerating the repair of corneal epithelium injury of the diabetic mouse.

Disclosed herein are antibody-oligonucleotide conjugates, pharmaceutical compositions, and methods for treating Sickle Cell Disease. The disclosure contemplates compositions and methods capable of binding a human hematopoietic stem cell marker conjugated to an oligonucleotide capable of hybridizing a target sequence. In some embodiments, the target sequence is a BCL11A transcript sequence. In some embodiments of the disclosure, the antibody-oligonucleotide conjugate promotes antisense- and / or RNA interference-mediated inhibition of BCL11A.

Familial adenomatous polyposis (FAP) patients harbor mutations in the APC gene and will develop adenoma and early colorectal cancer. Taking biopsies from non-adenomatous (NA) and adenomatous (A) colonic mucosa of FAP patients, we investigated the early events associated with FAP using the intestinal organoid model. In addition to their high proliferative capacity, NA- and A-organoids were characterized by cysts and cysts with buds, respectively, suggesting abnormal maturation. A-organoids were enriched in the stem cell marker LGR5 and dependent on EGF and TGFβ for their growth. Downstream of EGFR, AKT, β-catenin and YAP were found to be activated in A-organoids. While the p110β isoform of PI3K was predominant in A-organoids and essential for their growth, p110α was associated with the immature state of NA-organoids. Accordingly, the present invention relates to a method of treating Familial Adenomatous Polyposis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a PI3K inhibitor.

The invention discloses a steady-state long-term culture method of adipose-derived stem cells. The steady-state long-term culture method comprises the following steps: step 1, obtaining and pretreating adipose tissues; 2, constructing a basic culture system; step 3, regulating and controlling culture in stages; step 4, multi-dimensional steady state monitoring is carried out; 5, precise passage optimization is carried out; 6, whole-process pollution prevention and control; 7, cell quality identification; step 8, low-temperature preservation and recovery; according to the method, EGF, bFGF, TGF-beta1 and a Wnt inhibitor IWR-1 are added in stages, and an antioxidant is combined, so that long-term culture of more than 15 generations of AD-MSC is realized, the positive rate of a dry marker is always maintained to be greater than or equal to 95%, and the differentiation potential is not obviously reduced; a multi-dimensional steady-state monitoring system is established, the components of the culture medium and culture conditions are adjusted in real time, and the problems that the cell quality is not uniform and the inter-batch difference of the cell activity and the proliferation rate is smaller than or equal to 5% due to nutrient fluctuation and metabolic waste accumulation are avoided.

Disclosed herein are in vitro methods for detecting the presence of metabolically altered cells. Also disclosed herein are in vitro methods for detecting the presence of stationary cells. Disclosed herein are in vitro methods for detecting and predicting the presence of cancer. Disclosed herein are in vitro methods for monitoring response to anti-cancer therapy. The present disclosure analyzes the expression of at least one biomarker of pluripotent stem cells for detecting or predicting or monitoring cancer. Disclosed herein are related uses of at least one biomarker of pluripotent stem cell markers and methods of treatment including in vitro detection or prediction methods.

The invention relates to the field of medical biology, in particular to an AML (acute myelogenous leukemia) chemotherapy recurrent leukemia stem cell marker with a regulation function, and particularly relates to a PUF60 serving as the AML chemotherapy recurrent leukemia stem cell marker with the regulation function.

The present application is suitable for the field of biological detection and cosmetic safety evaluation technology, and provides a cosmetic raw material toxicity evaluation method based on co-culture of hair follicle stem cells and endothelial cells, which comprises the following steps: separating hair follicle stem cells and endothelial cells from mammalian skin tissue; establishing a non-contact co-culture system of hair follicle stem cells and endothelial cells by using a Transwell chamber, so as to simulate the intercellular interaction in the microenvironment of hair follicle stem cells; applying the cosmetic raw material to be tested to the co-culture system at a gradient concentration; detecting six indexes in six dimensions, i.e., cell viability, cell apoptosis, stem cell marker expression, endothelial barrier function, inflammatory factor release and genetic damage; calculating a comprehensive toxicity score according to a weighted comprehensive toxicity index model and determining a toxicity grade. The present application significantly improves the sensitivity and physiological relevance of toxicity detection, and provides a high-throughput, multi-index and standardized in-vitro alternative method for safety evaluation of cosmetic raw materials.

This invention discloses a colorectal cancer stem cell sex-inhibiting polypeptide, its expression vector, and its applications, belonging to the field of bioengineering technology. This invention is the first to discover the crucial role of ZCCHC14 protein in maintaining the characteristics of colorectal cancer stem cells, and based on this, develops an inhibitory polypeptide targeting ZCCHC14. Experiments have shown that this polypeptide can significantly downregulate the expression of colorectal cancer stem cell markers, upregulate the expression of differentiation markers, inhibit the spheroidization ability of stem cells, and significantly reduce EdU incorporation rate, effectively weakening the characteristics of colorectal cancer stem cells, promoting cancer cell differentiation, and inhibiting proliferation. It can be applied to the preparation of anti-colorectal cancer drugs, especially drugs that inhibit the proliferation of colorectal cancer cells, and has significant clinical application prospects.

The invention discloses application of myricetin in proliferation and differentiation of intestinal stem cells, and belongs to the field of organoid culture. After the organ-like model is treated by myricetin, the relative expression quantity of Lgr5 mRNA is remarkably increased, which indicates that the model can respond to intervention of myricetin, up-regulate expression of an intestinal stem cell marker Lgr5, and contribute to proliferation and tissue repair of intestinal stem cells. Immunofluorescence detection shows that the protein expression intensity of the myricetin group MUC2 is enhanced, which proves that the model can verify the promotion effect of myricetin on goblet cell differentiation and mucus secretion and improve the intestinal barrier function. QPCR detection proves that after myricetin treatment, the relative expression quantity of mRNA closely connected with related genes ZO-1, Occludin and Claudin-1 is remarkably increased, which indicates that the organ model can evaluate the protection and strengthening effects of myricetin on intestinal epithelium close connection, and has potential application value in treatment of intestinal barrier injury related diseases.